Peregrine Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Peregrine Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2025 Q2	$374K	Hold	1,147	–	–	0.01%	277
2025 Q1	$310K	Hold	1,147	–	–	0.01%	279
2024 Q4	$270K	Hold	1,147	–	–	0.01%	282
2024 Q3	$315K	Hold	1,147	–	–	0.01%	280
2024 Q2	$279K	Hold	1,147	–	–	0.01%	284
2024 Q1	$171K	Hold	1,147	–	–	﹤0.01%	282
2023 Q4	$220K	Hold	1,147	–	–	0.01%	280
2023 Q3	$203K	Hold	1,147	–	–	0.01%	282
2023 Q2	$218K	Hold	1,147	–	–	0.01%	286
2023 Q1	$230K	Hold	1,147	–	–	0.01%	281
2022 Q4	$273K	Hold	1,147	–	–	0.01%	277
2022 Q3	$230K	Sell	1,147 -233	-17%	-$46.7K	0.01%	282
2022 Q2	$201K	Hold	1,380	–	–	0.01%	286
2022 Q1	$225K	Hold	1,380	–	–	0.01%	289
2021 Q4	$234K	Hold	1,380	–	–	﹤0.01%	292
2021 Q3	$261K	Hold	1,380	–	–	0.01%	289
2021 Q2	$234K	Hold	1,380	–	–	﹤0.01%	290
2021 Q1	$195K	Hold	1,380	–	–	﹤0.01%	293
2020 Q4	$179K	Hold	1,380	–	–	﹤0.01%	289
2020 Q3	$201K	Sell	1,380 -93,386	-99%	-$13.6M	0.01%	301
2020 Q2	$14M	Sell	94,766 -13,909	-13%	-$2.06M	0.4%	103
2020 Q1	$11.8M	Sell	108,675 -43,962	-29%	-$4.79M	0.42%	96
2019 Q4	$17.6M	Sell	152,637 -38,648	-20%	-$4.45M	0.45%	96
2019 Q3	$15.4M	Sell	191,285 -39,757	-17%	-$3.2M	0.42%	107
2019 Q2	$16.8M	Buy	231,042 +37,821	+20%	+$2.74M	0.41%	103
2019 Q1	$18.1M	Sell	193,221 -3,580	-2%	-$335K	0.45%	95
2018 Q4	$14.3M	Sell	196,801 -1,237	-0.6%	-$90.2K	0.4%	109
2018 Q3	$17.3M	Buy	198,038 +19,433	+11%	+$1.7M	0.41%	112
2018 Q2	$17.6M	Buy	178,605 +36,886	+26%	+$3.63M	0.44%	98
2018 Q1	$16.9M	Sell	141,719 -6,680	-5%	-$796K	0.41%	96
2017 Q4	$18.9M	Sell	148,399 -16,465	-10%	-$2.09M	0.44%	86
2017 Q3	$19.4M	Sell	164,864 -34,224	-17%	-$4.02M	0.46%	79
2017 Q2	$15.9M	Sell	199,088 -22,821	-10%	-$1.82M	0.4%	97
2017 Q1	$11.7M	Buy	221,909 +15,477	+7%	+$818K	0.3%	130
2016 Q4	$7.73M	Buy	206,432 +22,033	+12%	+$825K	0.2%	227
2016 Q3	$12.5M	Buy	+184,399	New	+$12.5M	0.33%	128